KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inovio Pharmaceuticals (INO) Operating Expenses (2016 - 2025)

Inovio Pharmaceuticals (INO) has disclosed Operating Expenses for 16 consecutive years, with $17.5 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses fell 14.69% to $17.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $86.9 million through Dec 2025, down 22.85% year-over-year, with the annual reading at $86.9 million for FY2025, 22.85% down from the prior year.
  • Operating Expenses hit $17.5 million in Q4 2025 for Inovio Pharmaceuticals, down from $21.2 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $106.3 million in Q4 2021 to a low of $17.5 million in Q4 2025.
  • Historically, Operating Expenses has averaged $46.3 million across 5 years, with a median of $36.6 million in 2023.
  • Biggest five-year swings in Operating Expenses: soared 204.55% in 2021 and later tumbled 64.48% in 2023.
  • Year by year, Operating Expenses stood at $106.3 million in 2021, then crashed by 47.28% to $56.1 million in 2022, then crashed by 50.96% to $27.5 million in 2023, then decreased by 25.49% to $20.5 million in 2024, then dropped by 14.69% to $17.5 million in 2025.
  • Business Quant data shows Operating Expenses for INO at $17.5 million in Q4 2025, $21.2 million in Q3 2025, and $23.1 million in Q2 2025.